{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:28:33Z","timestamp":1789504113008,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:00:00Z","timestamp":1290470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2210-10-15","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T19:15:19Z","timestamp":1290539719000},"source":"Crossref","is-referenced-by-count":30,"title":["Pharmacokinetic and pharmacodynamic comparison of two \"pegylated\" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study"],"prefix":"10.1186","volume":"10","author":[{"name":"for the FarmaPEG Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idrian","family":"Garc\u00eda-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Gonz\u00e1lez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen M","family":"Valenzuela-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"D\u00edaz-Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Cruz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Nodarse-Cun\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cimara H","family":"Berm\u00fadez-Badell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ferrero-Bibilonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"P\u00e1ez-Meireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraldo","family":"Bello-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel R","family":"Castro-Odio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A","family":"L\u00f3pez-Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,23]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1006\/abio.1997.2128","volume":"247","author":"SP Monkarsh","year":"1997","unstructured":"Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, DeBarbieri B, Graves MC, Hollfelder K, Michel H, Palleroni A, Porter JE, Russoman E, Roy S, Pan YC: Positional isomers of monopegylated interferon a-2a: isolation, characterization and biological activity. Analytical Biochem. 1997, 247: 434-440. 10.1006\/abio.1997.2128.","journal-title":"Analytical Biochem"},{"key":"728_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1067\/mcp.2000.110973","volume":"68","author":"P Glue","year":"2000","unstructured":"Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S: Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000, 68: 556-567. 10.1067\/mcp.2000.110973.","journal-title":"Clin Pharmacol Ther"},{"key":"728_CR3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1742-1241.2003.tb10568.x","volume":"57","author":"P Ferenci","year":"2003","unstructured":"Ferenci P: PEG IFN alfa-2a (40 KD) (Pegasys) for the treatment of patients with chronic hepatitis C. Int J Clin Pract. 2003, 57: 610-615.","journal-title":"Int J Clin Pract"},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/00003495-200565060-00010","volume":"65","author":"GW Robins","year":"2005","unstructured":"Robins GW, Scott LJ, Keating GM: PEG IFN-alpha-2a (40 kD): a review of its use in the management of patients with chronic hepatitis B. Drugs. 2005, 65: 809-825. 10.2165\/00003495-200565060-00010.","journal-title":"Drugs"},{"key":"728_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s11095-005-5278-4","volume":"22","author":"J Ramon","year":"2005","unstructured":"Ramon J, Saez V, Baez R, Aldana R, Hardy E: PEGylated interferon-alpha2b: a branched 40 K polyethylene glycol derivative. Pharm Res. 2005, 22: 1374-1386. 10.1007\/s11095-005-5278-4.","journal-title":"Pharm Res"},{"key":"728_CR6","first-page":"267","volume":"14","author":"J Ferrero","year":"1997","unstructured":"Ferrero J, Duany L, Rem\u00f3n JY, Vega M, L\u00f3pez-Saura P: Nuevo programa de c\u00e1lculo. Cuantificaci\u00f3n de la actividad antiviral de interferones mediante la inhibici\u00f3n de efecto citopatog\u00e9nico utilizando el sistema de equipos SUMA. Biotecnolog\u00eda Aplicada. 1997, 14: 267-269.","journal-title":"Biotecnolog\u00eda Aplicada"},{"key":"728_CR7","first-page":"105","volume":"28","author":"VW Steinijans","year":"1990","unstructured":"Steinijans VW, Hauschke D: Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990, 28: 105-110.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"728_CR8","first-page":"72","volume":"28","author":"VW Steinijans","year":"1990","unstructured":"Steinijans VW, Hauschke D: A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990, 28: 72-78.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"728_CR9","first-page":"1","volume-title":"Statistical Approaches to Establishing Bioequivalence","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry","year":"2001","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. 2001, 1-45."},{"key":"728_CR10","first-page":"1","volume-title":"Note for Guidance on the Investigation of Bioavailability and Bioequivalence","author":"The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP)","year":"2002","unstructured":"The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2002, London, 1-18."},{"key":"728_CR11","first-page":"1","volume-title":"Guideline on Similar Medicinal Products Containing Recombinant Interferon Alpha","author":"European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP)","year":"2007","unstructured":"European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP): Guideline on Similar Medicinal Products Containing Recombinant Interferon Alpha. 2007, London, 1-7."},{"key":"728_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00126839-200405050-00003","volume":"5","author":"I Garcia-Garcia","year":"2004","unstructured":"Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Duconge J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P: Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004, 5: 271-280. 10.2165\/00126839-200405050-00003.","journal-title":"Drugs R D"},{"key":"728_CR13","doi-asserted-by":"publisher","first-page":"702A","DOI":"10.1002\/hep.510280302","volume":"28","author":"ZX Xu","year":"1998","unstructured":"Xu ZX, Hoffman J, Patel I, Jonbert P: Single-dose safety\/tolerability and pharmacokinetics\/pharmacodynamics (PK\/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-INF) and interferon \u03b1-2a (INF \u03b1-2a) to healthy subjects. Hepatology. 1998, 28: 702A-10.1002\/hep.510280302.","journal-title":"Hepatology"},{"key":"728_CR14","volume-title":"Dallas: American association for the study of liver diseases (AASLD)","author":"NE Algranati","year":"1999","unstructured":"Algranati NE, Sy S, Modi M: A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG IFN \u03b1-2a (PEG-INF) and may explain its enhanced efficacy in chronic hepatitis C (abst 120). Dallas: American association for the study of liver diseases (AASLD). 1999"},{"key":"728_CR15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2001.19.5.1312","volume":"19","author":"RJ Motzer","year":"2001","unstructured":"Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L: Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol. 2001, 19: 1312-1319.","journal-title":"J Clin Oncol"},{"key":"728_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2036.2007.03392.x","volume":"26","author":"R Bruno","year":"2007","unstructured":"Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G: Pharmacodynamics of PEG IFN alpha-2a and PEG IFN alpha-2b in interferon-na\u00efve patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther. 2007, 26: 369-376. 10.1111\/j.1365-2036.2007.03392.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"728_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200140100-00001","volume":"40","author":"ML Chen","year":"2001","unstructured":"Chen ML, Lesko LJ: Individual bioequivalence revisited. Clin Pharmacokinet. 2001, 40: 701-706. 10.2165\/00003088-200140100-00001.","journal-title":"Clin Pharmacokinet"},{"key":"728_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2008","unstructured":"Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008, 8: 559-568. 10.1038\/nri2314.","journal-title":"Nat Rev Immunol"},{"key":"728_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jcp.10290","volume":"195","author":"A Garcia-Lora","year":"2003","unstructured":"Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003, 195: 346-355. 10.1002\/jcp.10290.","journal-title":"J Cell Physiol"},{"key":"728_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1389200024605082","volume":"3","author":"C Murr","year":"2002","unstructured":"Murr C, Widner B, Wirleitner B, Fuchs D: Neopterin as a marker for immune system activation. Curr Drug Metab. 2002, 3: 175-187. 10.2174\/1389200024605082.","journal-title":"Curr Drug Metab"},{"key":"728_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2165\/00003088-199733020-00005","volume":"33","author":"BG Reigner","year":"1997","unstructured":"Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P: An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet. 1997, 33: 142-152. 10.2165\/00003088-199733020-00005.","journal-title":"Clin Pharmacokinet"},{"key":"728_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jps.1167","volume":"91","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Derendorf H: Pharmacokinetic\/pharmacodynamic studies in drug product development. J Pharm Sci. 2002, 91: 18-31. 10.1002\/jps.1167.","journal-title":"J Pharm Sci"},{"key":"728_CR23","first-page":"1","volume-title":"Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Non-clinical and clinical issues","author":"European Medicines Agency","year":"2006","unstructured":"European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Non-clinical and clinical issues. 2006, London, 1-8."},{"key":"728_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2893.2007.00944.x","volume":"15","author":"N Napoli","year":"2008","unstructured":"Napoli N, Giannelli G, Antonaci A, Antonaci S: The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hepat. 2008, 15: 300-304. 10.1111\/j.1365-2893.2007.00944.x.","journal-title":"J Viral Hepat"},{"key":"728_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009, 361: 580-593. 10.1056\/NEJMoa0808010.","journal-title":"N Engl J Med"},{"key":"728_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000238464","volume":"32","author":"G Gross","year":"1986","unstructured":"Gross G, Ikenberg H, Roussaki A, Drees N, Schopf E: Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen. Chemotherapy. 1986, 32: 537-541. 10.1159\/000238464.","journal-title":"Chemotherapy"},{"key":"728_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/00006454-199711000-00009","volume":"16","author":"M Marcellini","year":"1997","unstructured":"Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, Rapicetta M: High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J. 1997, 16: 1049-1053. 10.1097\/00006454-199711000-00009.","journal-title":"Pediatr Infect Dis J"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/1097-0142(20001001)89:7<1490::AID-CNCR11>3.0.CO;2-V","volume":"89","author":"PA Ascierto","year":"2000","unstructured":"Ascierto PA, Daponte A, Parasole R, Perrone F, Carac\u00f2 C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G: Intermediate dose recombinant interferon - alpha as second - line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer. 2000, 89: 1490-1494. 10.1002\/1097-0142(20001001)89:7<1490::AID-CNCR11>3.0.CO;2-V.","journal-title":"Cancer"},{"key":"728_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1089\/jir.2006.26.849","volume":"26","author":"A Boulestin","year":"2006","unstructured":"Boulestin A, Kamar N, Sandres-Saun\u00e9 K, Alric L, Vinel JP, Rostaing L, Izopet J: Pegylation of IFN-alpha and antiviral activity. J Interferon Cytokine Res. 2006, 26: 849-853. 10.1089\/jir.2006.26.849.","journal-title":"J Interferon Cytokine Res"},{"key":"728_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2249.1997.269-ce1161.x","volume":"107","author":"EP Corssmit","year":"1997","unstructured":"Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA: Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol. 1997, 107: 359-363. 10.1111\/j.1365-2249.1997.269-ce1161.x.","journal-title":"Clin Exp Immunol"},{"key":"728_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2004.07.013","volume":"156","author":"YX Wang","year":"2004","unstructured":"Wang YX, Xu WG, Sun XJ, Chen YZ, Liu XY, Tang H, Jiang CL: Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2. J Neuroimmunol. 2004, 156: 107-112. 10.1016\/j.jneuroim.2004.07.013.","journal-title":"J Neuroimmunol"},{"key":"728_CR32","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: PEG IFN alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343: 1666-1672. 10.1056\/NEJM200012073432301.","journal-title":"N Engl J Med"},{"key":"728_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL, H\u00e4ussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: PEG IFN alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056\/NEJMoa020047.","journal-title":"N Engl J Med"}],"container-title":["BMC Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2210-10-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2210-10-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2210-10-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T08:08:55Z","timestamp":1685866135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1186\/1471-2210-10-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1186\/1471-2210-10-15","relation":{},"ISSN":["1471-2210"],"issn-type":[{"value":"1471-2210","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,23]]},"article-number":"15"}}